SVB Wealth’s Travere Therapeutics TVTX Stock Holding History

SVB Wealth’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-36	Closed	-$645	–	1543
2025 Q1	$645	Buy	+36	New	+$731	﹤0.01%	1382

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SVB Wealth's TVTX Position: Q2 2025 in Review

SVB Wealth sold out of Travere Therapeutics (TVTX) in Q2 2025, closing a stake of 36 shares — an estimated $645 sold.

SVB Wealth first reported a position in TVTX in Q1 2025 and held it in 1 quarter. The position peaked at $645 in Q1 2025. 211 funds tracked by Wall St. Rank hold TVTX as of Q2 2025.

SVB Wealth reported no remaining Travere Therapeutics position as of Q2 2025 after selling out during the quarter.
SVB Wealth sold 36 Travere Therapeutics shares in Q2 2025, an estimated $645.
SVB Wealth first reported a position in Travere Therapeutics in Q1 2025 and held it in 1 quarter.
SVB Wealth's Travere Therapeutics position peaked at $645 in Q1 2025.
211 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2025.

Based on SVB Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.